99095-19-9

Basic information

• Product Name: (+/-)-4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]-1-hydroxyethyl]phenol hydrochloride
• Synonyms: (+/-)-4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]-1-hydroxyethyl]phenol hydrochloride
• CAS NO: 99095-19-9
• Molecular Weight: 0
• EINECS: 415-170-5
• Mol File: 99095-19-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (+/-)-4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]-1-hydroxyethyl]phenol hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)-4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]-1-hydroxyethyl]phenol hydrochloride(99095-19-9)
• EPA Substance Registry System: (+/-)-4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]-1-hydroxyethyl]phenol hydrochloride(99095-19-9)

Safety Data

• Hazard Codes: Xn
• Statements: 20/22-43
• Safety Statements: 24-26-37
• Hazardous Substances Data: 99095-19-9(Hazardous Substances Data)

Usage

General Description

The chemical (+/-)-4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]-1-hydroxyethyl]phenol hydrochloride is a compound that acts as a α1-adrenergic receptor agonist. It is commonly used in the treatment of hypotension, as it can stimulate the adrenergic receptors in the body and increase blood pressure. (+/-)-4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]-1-hydroxyethyl]phenol hydrochloride is structurally related to phenylephrine, and it works by constricting blood vessels and increasing systemic vascular resistance. It is often used in medical settings to elevate blood pressure and counteract the effects of severe hypotension. Additionally, it has been studied for its potential use in the treatment of spinal anesthesia-induced hypotension. The hydrochloride salt form of this compound is the most commonly used for medical applications due to its stability and solubility in water.

Upstream product

• 283585-95-5 S,R-ractopamine 
• 22214-30-8 4-(4'-hydroxyphenyl)but-3-en-2-one 
• 770-05-8 octopamine hydrochloride 
• 97825-25-7 1-(4-hydroxyphenyl)-2-[3-(4-hydroxyphenyl)-1-methylpropylamino]ethanol 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF RACTOPAMINE HYDROCHLORIDE VIA NOVEL INTERMEDIATES

The present disclosure describes the new methods of preparation of Ractopamine which are superior to state of art by involving comparatively better and mild reaction conditions. The method of preparation involves following steps: In the first embodiment, 4-(4-hydroxyphenyl)-3-butene-2-one is prepared by condensation of 4-hydroxybenzaldehyde with acetone in the presence of sodium hydroxide/hydrochloric acid. In the next step, 4-(4-hydroxyphenyl)-3-butene-2-one undergoes hydrozination with 4-(-2-amino-1- hydroxyl ethyl) phenolhydrochloride in the presence of base using Pd/C/H2 as a catalyst in methanol/ethanol as solvent to yield Ractopamine base. In another embodiment, advancement over the previous scheme is use of Raney Ni/H2 instead of Pd/C as a catalyst. In yet another embodiment, 2-amino-1-(4-hydroxyphenyl) ethanone hydrochloride reacts with 4-(4-hydroxyphenyl)-butane -2-one in the presence of base and raney nickel/H2 as a catalyst. Compared to the prior art reports where Pd/C was used as a catalyst, Raney Ni is used in the present embodiment which is comparatively economical and better catalyst.

Methods of Accelerating Muscle Growth, Decreasing Fat Deposits and Improving Feed Efficiency in Livestock Animals

A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal. Feed preparation, compositions and pharmaceutical preparations including therapeutically effective amounts of a pure or substantially pure RR-isomer of ractopamine are disclosed